Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.3.3 to v3.3.4.
    Difference
    0.0%
    Check dated 2026-01-15T02:45:29.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    A consolidated Locations section listing all participating states has been added, and the previous per-state location entries were removed. The page shows Revision: v3.3.3.
    Difference
    1%
    Check dated 2025-12-24T21:38:38.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    New data added: EU CTIS number 2024-512005-87-00 and study completion date 2026-05-01, plus updated last update indicators (2025-11-28, 2025-11). Some older timestamps and the 'Last Update Posted' entry were removed.
    Difference
    0.1%
    Check dated 2025-12-16T15:53:07.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The Publications section is now automatically filled from PubMed and may not relate to the study; the page revision is now v3.3.2 (up from v3.2.0).
    Difference
    0.0%
    Check dated 2025-11-25T10:10:26.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    - Removed the government funding status notice banner. Study details, eligibility criteria, and other trial information remain unchanged.
    Difference
    0.1%
    Check dated 2025-11-18T03:27:21.000Z thumbnail image
  8. Check
    70 days ago
    Change Detected
    Summary
    Added the location 'Tainan, Taiwan' to the study locations and removed 'Tainan City, Taiwan'. This updates how sites in Taiwan are identified and located for potential participants.
    Difference
    0.0%
    Check dated 2025-11-10T22:07:26.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.